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Summary Between January 1981 and December 1985, 122 patients with non-seminomatous germ cell
tumours (NSGT) were seen at a regional referral centre. Of these, a total of 98 patients received
chemotherapy for metastatic disease. Treatment was given within collaborative EORTC Urology group
studies, all of which involved cis-platin-containing schedules. Ninety patients had tumours of testicular origin,
and their 2 year actuarial survival rate is 91%; 8 had tumours of extragonadal origin and their 2 year
actuarial survival is 25%. Patients with testicular tumours were subdivided by volume of metastatic disease
using the recommendations of the Testicular Cancer Subgroup of the MRC Urological Cancer Working Party
and survival was significantly worse in the group with very large volume metastatic disease (VLVM, 57%)
compared with the groups with large volume metastases (LVM, 100%) and small volume metastases (SVM,
98%). There were 31 patients with Stage I disease at presentation; of these 6 were treated by prophylactic
abdominal radiotherapy and 25 were managed by a policy of surveillance only. Seven of these Stage I patients
(23%) relapsed with metastatic disease (median 8 months); all have been successfully treated with
chemotherapy.
These data confirm that the majority of patients now presenting with metastatic NSGCT are curable with
chemotherapy, but that a small proportion with very large volume metastases or extragonadal tumours
require alternative chemotherapy schedules.
The improvement in survival over the past ten years of
patients with disseminated germ cell tumours has been well
documented and has principally been due to improvements
in chemotherapy schedules following the introduction of cis-
platin and etoposide. A review of recent studies indicates
that 80-90% of patients will be long term survivors
(Einhorn, 1986). A multicentre study of the MRC Testicular
Tumour Subgroup of the Urological Working Party reported
a 3 year survival of 89% but presentation with bulk
metastatic disease or high tumour marker levels (human
chorionic gonadotrophin [HCG] or alphafoetoprotein [AFP])
was associated with a poor prognosis (Medical Research
Council Working Party, 1985).
The aim of this study was to review experience in the
presentation and management of patients with this disease,
over a 5 year period at a single regional referral centre, and
to place this in perspective against the background of
national data.
Materials and methods
Analysis was carried out on 122 consecutive patients referred
mainly from urologists in the West of Scotland to the
Department of Medical Oncology, Gartnavel General
Hospital, between January 1981 and December 1985.
Minimum follow-up is one year. Histological diagnosis of
malignant teratoma was made at the time of orchidectomy in
112 patients and nodal biopsy in 2 patients with primary
testicular tumours: or by biopsy of extra-gonadal sites in 7
(retroperitoneal mass n=5, mediastinal nodes n = 1, pineal
gland n= 1). A single patient was diagnosed on the basis of
an HCG 243,000 UI and multiple pulmonary metastases.
Investigations included tumour marker estimation (#HCG
and AFP), serum biochemistry, liver function tests, chest X-
ray, CT scan of chest, abdomen and pelvis and bipedal
lymphangiogram in patients with normal CT scans. Tumour
histology was reviewed by the department of Pathology if
the report from the referring hospital was equivocal.
Of the 114 patients with testicular germ cell tumours, 31
had stage I disease and 83 metastatic teratoma (Peckham et
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al., 1983). Seven of the 83 patients presenting with
metastases had been previously irradiated for Stage I disease
(sites of relapse are shown in Table I). A single patient was
referred with relapsed disease after prior chemotherapy.
Chemotherapy regimes are listed in Table II. Eligible
patients (n=70) were entered into collaborative protocols of
the EORTC Urology Group which were current at the time
of referral. These all involved cis-platin-containing regimens,
in combination with bleomycin and etoposide, or bleomycin
and vinblastine, or etoposide alone. Full details of these
schedules have been presented elsewhere (Stoter et al., 1986;
Stoter et al., 1987). Treatment was with four (5-day) courses
of chemotherapy or six courses if not in tumour marker
remission after four. Residual masses were surgically resected
where possible and further chemotherapy given if resected
specimens showed active tumour. Patients ineligible for
EORTC studies on the basis of prior radiotherapy (n=7),
chemotherapy (n=1), extragonadal primary site (n=8) or
other (n= 12) also received platinum based combinations as
shown in Table II.
Patients with metastatic disease were staged using the
Royal Marsden Hospital classification and then subdivided
according to the criteria suggested by the MRC Testicular
Tumour Working Party (see Table III). Survival was calcu-
lated from date of orchidectomy in Stage I patients and from
date of first chemotherapy in all others. Actuarial survival
curves were prepared using the life table method and
differences analysed by the log rank test.
Table I Pattern of relapse in Stage I patients
No prior
irradiation Prior irradiation
IM IM: surveillance in Glasgow
MRC surveillance IIA
IIB IIIA (Mediastinum only)
IIB IIIB
IVLI
IIB IVL2+Brain
Surveillance without CT IIC IVL3
IVC+Liver
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Table II Chemotherapy schedules
No. patients treated
EORTC
studies Other
(1)
PVB
Cis-platin 20mgm 2 day 1 to 5
Vinblastine 0.15mgkg1 or 0.2mgkg-
or 6mgm-2
Bleomycin 30mg i.v. or i.m. weekly x 12
(2)
BEP
as above
substituting etoposide 120mgm-2
for vinblastine. a
21 14
days 1 and 2
22 5
ays 1, 3, 5
(3)
Alternating courses PVB - BEP - PVB - BEP
(4)
EP
Cis-platin 20mg m2 days 1-5
Etoposide 120mgm-2 days 1, 3, 5
(5)
PVB+Methotrexate It. 12.5mg day 1
IV lgmm-2dayI0
Schedules 1-5 q 3 weekly
(6)
BOP
Cis-platin 50mgm-2 days 1 and 2
Vincristine 2mg day 1 T q 10-21 days
Bleomycin 30mg i.v. day 1 J
(7)
POMB/ACE*
Cis-platin 40mgm 2 days 1-3
Vincristine 2mg i.v. day 1
Methotrexate 100mgm-2 bolus
200 mg m-2 12h infusion day 1
Bleomycin 15mg i.v. 12h infusion days 2 and 3
Etoposide 150mgm-2 days 1-3
Actinomycin D 0.5mg i.v. days 1-3
Cyclophosphamide 500mgm-2 day 3
POMB: 3 cycles 1-10 days
then alternating POMB/ACE q 21 days
*Newlands et al., 1986.
Table III Clinical staging for testicular tumours
Royal Marsden Hospital classification
Lymphogram negative, no evidence of metastases.
No evidence of metastases but persistently elevated AFP
and/or HCG levels.
II. Para-aortic node metastases:
A, metastases<2cm diameter;
B, Metastases 2-5cm diameter;
C, metastases> 5cm diameter.
III. Supra-diaphragmatic and infra diaphragmatic lymph node
involvement: abdominal status A, B and C as above.
IV. Extralymphatic metastases: abdominal status A, B and C as
above.
Lung status:
LI; < 3 metastases;
L2; multiple, none>2cm diameter;
L3; multiple, one or more>2cm diameter.
Liver status: H +, liver involvement.
MRC Working Party classification
Small volume: stages TM, IIA, TIB, IIIA, TuIB, IVALI, IVAL2,
IVBLI, IVNL2.
Large volume: stages TIC, IIIC, IVCLI, IVCL2.
Very large volume: L3 pulmonary disease, liver involvement. Central
nervous system spread or bone disease.
Results
Of the 31 patients (26%) who were clinically Stage I, 16
entered a surveillance study conducted by the MRC
Testicular Cancer Subgroup and were monitored with monthly
clinical examination, chest radiology and tumour marker
estimation with bimonthly CT scanning. Six patients received
adjuvant irradiation (4,OOOcGy in 20 fractions over 28 days
to the para-aortic and ipsilateral inguinal nodes) and 9 were
followed up without the benefit of computerised tomo-
graphy. There have been 7 relapses in the whole group
(23%) all of whom achieved complete remission with chemo-
therapy and their disease free survival at a minimum of 2
years from diagnosis is 100%. Only one of these seven had
received adjuvant irradiation. The median time to relapse
was 8 months (range 2-12 months). The frequency of relapse
was related to the histology of the primary tumour, being
none of 3 differentiated, 2 of 13 intermediate (MTI) and 5 of
14 undifferentiated (MTU) teratomas.
Ninety-eight patients received chemotherapy and the
distribution by volume of metastatic disease is shown in
Table IV. This includes all relapsed Stage I tumours, the one
patient previously treated with chemotherapy, and the eight
patients with primary extragonadal NSCG tumours. The
actuarial survival curves for these patients are shown in
Figure 1. This demonstrates signficantly worse 2 year
survival for those patients presenting with VLVM (57%) and
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extragonadal tumours (25%). There were insufficient patient
numbers to analyse tumour marker levels as an independent
prognostic variable (see Table IV).
Table V outlines the specific cause of death of the 8
patients in the testicular tumour group and the 6 patients
with extragonadal tumours. Only one death was directly
treatment related: this was fatal respiratory failure as a
consequence of bleomycin induced fibrosis with super-
imposed infection and* haemorrhage during a period of
pancytopenia. The patient whose cause of death is uncertain
died suddenly at home, 10 days after his 3rd treatment
course: he had no leucopenia 2 days previously and post
mortem was non-contributory.
Respiratory failure was the terminal event in the 3 patients
with IVL3 advanced disease, 2 of whom presented with
respiratory symptoms. The fourth patient had massive
mediastinal disease and died of cardiac failure; permission
for post mortem was refused but pericardial involvement
may have been contributory. Three of 8 patients with drug
resistant disease achieved a marker complete remission but
all relapsed within 2 months; the others responded
transiently (PR in 3) but ultimately progressed despite
alternative chemotherapy. No significant second responses
were seen.
Discussion
The actuarial 2 year survival of 91%/o in patients treated from
1981-1985 compares favourably with that reported from
other centres. Although late relapses do occur occasionally,
most relapses are evident within one year of treatment, thus
the survival data are unlikely to be affected significantly by
longer follow up. A multicentre study from the MRC
Working Party on Testicular Tumours reported a 3 year
survival of 89% in patients treated from 1981-1982, which is
almost identical to this series. The poor prognosis in patients
with extragonadal tumour is probably related to volume of
disease at presentation, since 5 of the 8 patients had tumour
which would have been defined as very large volume
(VLVM). Previous studies also indicate that patients
presenting with extragonadal tumours fare less well than
those with testicular primary sites (Hainsworth et al., 1982).
True drug resistant disease was uncommon in testicular
tumours and apparently confined to those patients
presenting with VLVM (3 of 17). However, S of 8 extra-
gonadal primary tumours were drug resistant including 3
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Figure 1 Actuarial survival according to volume of disease for
98 patients with germ cell tumour. Small volume (51 cases),
large volume ---- (22 cases), very large volume - -
(17 cases), extragonadal . (8 cases). Difference is significant
(chi-square =50.57, df=3, P<0.005).
with very large and 2 with large volume disease. These data
support the hypothesis that the incidence of spontaneous
mutations conferring drug resistance increases with tumour
size (Goldie & Coldman, 1979).
A number of patients presented with advanced disease and
died before chemotherapy could be effective. The median
duration of symptoms in those patients whose death was due
to advanced disease was 8 months (4-12). In the 9 instances
where symptoms exceeded 4 months in duration, delay in
diagnosis following self-referral was responsible in 4 patients,
three of whom presented with back pain as a result of Stage
Ilc disease (2 extragonadal primary). However, 2 patients
ignored testicular swelling for more than 1 year. These
observations indicate a continuing need for professional and
public education.
One quarter of patients presented with Stage I disease and
within the surveillance only study, all patients that relapsed
are alive and disease free following treatment with chemo-
therapy. Analysis of data from the MRC surveillance study
has identified factors which will predict a high rate of relapse
in Stage I disease, (MTU histology, absence of yolk sac
elements, presence of cord or vascular invasion: Freedman et
al., 1987) and it is currently recommended that such patients
should receive adjuvant chemotherapy.
Table IV (a) Tumour marker levels by volume of metastatic disease
(b) Survival.
Median
(a) No. marker No. HCG>J,000
Volume producing and/or AFP>500 HCG AFP
Small 29/51 4 46 154
(3-9,981) (5-1,617)
Large 16/22 9 476 303
(4-9,000) (8-14,025)
Very large 16/17 10 6,034 593
(4-450,000) (10-4,505)
Extragonadal 5/8 4 15 and 243,000 777
(500-860)
(b) Volume No. ofpatients 2 year survival (%)
Small 51 98
Large 22 100
Very large 17 57
Extragonadal 8 25TREATMENT OF GERM CELL TUMOURS 185
Table V Cause of death in 14 patients with germ cell tumours treated with
chemotherapy
Testicular
Stage
Survivalfrom date Cause of
Patient Pathology RMH MRC of1st chemo (months) death
1 MTU IVAL3 VLVM 9 Resistant
2 MTU IM SVM 13 Treatment
related
3 MTD IVCL3 VLVM 17 Resistant
4 MTT IVCL3 VLVM 2 days Advanced
5 MTU IVCL3 VLVM 4 days Advanced
6 MTU IVCL3 VLVM 14 Resistant
7 MTI IVBL3 VLVM 2 Uncertain
8 MTI IVCL3 VLVM 16 days Advanced
Extragonadal
Stage
Survivalfrom date Cause of
Patient Pathology RMH MRC of Ist chemo (months) death
I MTU IVCH+ VLVM 16 Resistant
2 MTT IVCL3H+ VLVM 21 Resistant
3 MTU III LVM 6 days Advanced
4 MTI IIC LVM 14 Resistant
5 MTT IVCL3 VLVM 13 Resistant
6 MTU IIC LVM 6 Resistant
Advanced. overwhelming disease at presentation.
Resistant: progression despite multiple chemotherapy regimes.
These results from a regional referral centre confirm the
improvement in survival over the past ten years for non-
seminomatous germ cell tumours and indicate that the great
majority of patients can expect to be cured with drug
combinations which include cis-platin and etoposide. There
remains a group of patients with very large volume
metastatic disease for whom alternative treatment regimes
are required and intensive multi-drug combinations are being
evaluated. These include the use of higher doses of drugs,
shorter intervals between treatment cycles, and inclusion of
alternative agents of proven efficacy (eg ifosfamide) in first
line combinations (Wheeler et al., 1982).
We are grateful to the Urologists and General Surgeons from the
West of Scotland for patient referral, to the Cancer Research
Campaign for support, particularly of the Clinical Trials Unit and
to Liz Sharkie for typing the manuscript.
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